Elevance Health, Inc. (NYSE:ELV – Get Free Report) Director Ramiro Peru bought 1,000 shares of the firm’s stock in a transaction on Thursday, November 19th. The stock was acquired at an average cost of $383.86 per share, with a total value of $383,860.00. Following the completion of the transaction, the director directly owned 11,908 shares of the company’s stock, valued at approximately $4,571,004.88. This represents a 9.17% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Elevance Health Stock Up 1.1%
Elevance Health stock opened at $394.40 on Friday. The company has a market capitalization of $85.21 billion, a P/E ratio of 16.82, a P/E/G ratio of 2.13 and a beta of 0.63. The firm’s fifty day simple moving average is $415.92 and its 200-day simple moving average is $376.97. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 0.68. Elevance Health, Inc. has a 1-year low of $274.84 and a 1-year high of $450.69.
Elevance Health (NYSE:ELV – Get Free Report) last issued its quarterly earnings data on Wednesday, October 21st. The company reported $6.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.71 by $2.28. The firm had revenue of $50.44 billion during the quarter, compared to analysts’ expectations of $49.28 billion. Elevance Health had a net margin of 2.55% and a return on equity of 14.97%. Elevance Health’s revenue for the quarter was up .7% on a year-over-year basis. During the same period in the prior year, the company posted $6.03 earnings per share. Sell-side analysts forecast that Elevance Health, Inc. will post 29.16 earnings per share for the current fiscal year.
Elevance Health Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be issued a $1.72 dividend. This represents a $6.88 annualized dividend and a yield of 1.7%. The ex-dividend date is Friday, December 4th. Elevance Health’s dividend payout ratio (DPR) is 29.34%.
Hedge Funds Weigh In On Elevance Health
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Meiji Yasuda Asset Management Co Ltd. acquired a new stake in shares of Elevance Health in the 2nd quarter valued at $2,086,000. Stoneridge Investment Partners LLC acquired a new position in shares of Elevance Health during the second quarter valued at $970,000. State Street Corp lifted its stake in shares of Elevance Health by 1.3% during the second quarter. State Street Corp now owns 10,426,610 shares of the company’s stock valued at $4,032,283,000 after acquiring an additional 137,914 shares during the period. Farther Finance Advisors LLC boosted its holdings in Elevance Health by 27.1% in the third quarter. Farther Finance Advisors LLC now owns 11,826 shares of the company’s stock valued at $4,598,000 after acquiring an additional 2,518 shares during the last quarter. Finally, State of Wyoming acquired a new position in Elevance Health during the 2nd quarter valued at about $1,765,000. 89.24% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on ELV. Guggenheim boosted their target price on shares of Elevance Health from $460.00 to $485.00 and gave the stock a “buy” rating in a research report on Thursday, October 22nd. UBS Group raised their price target on Elevance Health from $460.00 to $523.00 and gave the company a “buy” rating in a research report on Thursday, October 22nd. Robert W. Baird lifted their price target on Elevance Health from $393.00 to $406.00 and gave the stock a “neutral” rating in a research report on Thursday, October 22nd. Barclays upped their price objective on shares of Elevance Health from $469.00 to $472.00 and gave the company an “overweight” rating in a research report on Thursday, October 22nd. Finally, TD Cowen lifted their price target on shares of Elevance Health from $465.00 to $495.00 and gave the stock a “buy” rating in a research note on Friday, October 23rd. Sixteen equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, Elevance Health has an average rating of “Moderate Buy” and an average price target of $458.91.
View Our Latest Stock Analysis on ELV
About Elevance Health
Elevance Health, Inc. is a U.S. health benefits and services company. Formerly known as Anthem, Inc., it adopted the Elevance Health name in 2022 while retaining the Anthem brand for many of its health plans. The company offers medical, pharmacy, dental, vision and behavioral health coverage, including plans for individuals and employers as well as programs serving Medicare and Medicaid members. Its services also include care management, pharmacy benefit services and other health-related capabilities through its Carelon business.
Featured Articles
- Five stocks we like better than Elevance Health
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
